Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | IDH2 | P48735 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8911647 | 0.94 | TRPV1 (0.59) | TRPV1CA1CA2MMP1MMP2 | |
| SCHEMBL9239964 | 0.94 | TRPV1 (0.59) | TRPV1CA1CA2MMP1MMP2 | |
| SCHEMBL8911186 | 0.94 | TRPV1 (0.59) | TRPV1CA1CA2MMP1MMP2 | |
| SCHEMBL15199080 | 0.87 | ALDH1A1 (0.56) | TRPV1ALDH1A1LMNATSHRKMT2A | |
| SCHEMBL13753685 | 0.85 | CA1 (0.64) | TRPV1CA1CA2MMP1MMP2 | |
| SCHEMBL10630564 | 0.84 | CA1 (0.52) | TRPV1CA1CA2MMP1MMP2 | |
| SCHEMBL10628669 | 0.84 | CA1 (0.52) | TRPV1CA1CA2MMP1MMP2 | |
| SCHEMBL1148961 | 0.82 | CA1 (0.60) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5183968 | 0.82 | CA1 (0.57) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL16508871 | 0.82 | CA1 (0.59) | CA1CA2MMP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101111240-B | Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostate hyperp | LOHMANN THERAPIE SYST LTS | 2011-09-21 | — | — | CN | claimed |
| US-7700654-B2 | Isolation of N-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of N-butylbenzenesulfonamide and benzenesulfonamide derivatives for treating benign prostatic hyperplasia and/or prostate carcinoma | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2010-04-20 | — | — | US | claimed |
| US-7700654-B2 | Isolation of N-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of N-butylbenzenesulfonamide and benzenesulfonamide derivatives for treating benign prostatic hyperplasia and/or prostate carcinoma | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-20080177107-A1 | Isolation of N-Butylbenzenesulfonamide, Synthesis of Benzenesulfonamide Derivatives, and Use of N-Butylbenzenesulfonamide and Benzenesulfonamide Derivatives for Treating Benign Prostatic Hyperplasia and/or Prostate Carcinoma | LTS LOHMANN THERAPIE-SYSTEME (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080177107-A1 | Isolation of N-Butylbenzenesulfonamide, Synthesis of Benzenesulfonamide Derivatives, and Use of N-Butylbenzenesulfonamide and Benzenesulfonamide Derivatives for Treating Benign Prostatic Hyperplasia and/or Prostate Carcinoma | LTS LOHMANN THERAPIE-SYSTEME (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177107-A1 | Isolation of N-Butylbenzenesulfonamide, Synthesis of Benzenesulfonamide Derivatives, and Use of N-Butylbenzenesulfonamide and Benzenesulfonamide Derivatives for Treating Benign Prostatic Hyperplasia and/or Prostate Carcinoma | BPHL, BRDT, NBAS | TRPV1 1315/4885CA1 1737/4885CA2 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.